Trial Profile
A Phase 1 Study to Assess Safety and Tolerability of Tremelimumab and Durvalumab, Administered With High Dose Chemotherapy and Autologous Stem Cell Transplant (HDT/ASCT)
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Melphalan; Pneumococcal 13-valent CRM197 vaccine conjugate
- Indications Multiple myeloma
- Focus Adverse reactions
- 04 May 2018 Status changed from active, no longer recruiting to discontinued.
- 06 Mar 2018 Planned End Date changed from 1 Jun 2021 to 1 Jul 2018.
- 01 Sep 2017 Status changed from recruiting to active, no longer recruiting.